<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background:The chromosome 9p21.3 region has been implicated in the pathogenesis of <z:e sem="disease" ids="C0346429" disease_type="Neoplastic Process" abbrv="">multiple cancers</z:e>.Methods:We systematically examined up to 203 tagging SNPs of 22 genes on 9p21.3 (19.9-32.8 Mb) in eight case-control studies: <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e>, <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> (EC), <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> (CA), oesophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>), gastric cardia <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> (OS) </plain></SENT>
<SENT sid="1" pm="."><plain>We used logistic regression to perform single SNP analyses for each study separately, adjusting for study-specific covariates </plain></SENT>
<SENT sid="2" pm="."><plain>We combined SNP results across studies by fixed-effect meta-analyses and a newly developed subset-based statistical approach (ASSET) </plain></SENT>
<SENT sid="3" pm="."><plain>Gene-based P-values were obtained by the minP method using the Adaptive Rank Truncated Product program </plain></SENT>
<SENT sid="4" pm="."><plain>We adjusted for multiple comparisons by Bonferroni correction.Results:Rs3731239 in cyclin-dependent kinase inhibitors 2A (CDKN2A) was significantly associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> (P=7 × 10(-6)) </plain></SENT>
<SENT sid="5" pm="."><plain>The CDKN2A-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> association was further supported by gene-based analyses (Pgene=0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>In the meta-analyses by ASSET, four SNPs (rs3731239 in CDKN2A, rs615552 and rs573687 in CDKN2B and rs564398 in CDKN2BAS) showed significant associations with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> and EC (P&lt;2.46 × 10(-4)) </plain></SENT>
<SENT sid="7" pm="."><plain>One SNP in MTAP (methylthioadenosine phosphorylase) (rs7023329) that was previously associated with <z:hpo ids='HP_0002861'>melanoma</z:hpo> and <z:e sem="disease" ids="C0027960" disease_type="Neoplastic Process" abbrv="">nevi</z:e> in multiple genome-wide association studies was associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, CA and OS by ASSET (P=0.007).Conclusion:Our data indicate that genetic variants in CDKN2A, and possibly nearby genes, may be associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> and several other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, further highlighting the importance of 9p21.3 genetic variants in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>